Resources
Most pharma launches miss because of how they are run, not what they are.
Two thirds of drug launches miss first year forecast. The cause is rarely the molecule. The cause is the commercial system.
By every measurable indicator, pharma is getting worse at commercializing the science it spends a decade developing. Two thirds of launches miss first year sales forecasts. One in ten launches between 2020 and 2024 cleared the 100 million dollar threshold, half the rate of the previous five years.
The default explanations are wrong. It is not crowded markets. It is not noisier trials. It is not weaker molecules. The data, when looked at honestly, points to organizational discipline. Companies that combine clinical differentiation with manufacturer commitment achieve 67 percent overperformance. Companies that have only the molecule achieve 49 percent. Eighteen points. That is the entire commercial opportunity, and it has almost nothing to do with the science.
The companies that win pharma launches do unglamorous things. They start commercial work 30 plus months before approval. They build manufacturing capacity before demand materializes. They model patient flow alongside HCP intent and payer access. They concentrate launch accountability in a single named leader. The math is clear. The will is rare. This collection is for operators who want to close the gap before their next launch.
Key Insights
What the data is showing.
Two thirds of pharma drug launches miss first year sales forecasts.
Clinical differentiation alone produces 49 percent overperformance. Add manufacturer commitment and the number jumps to 67 percent.
Lilly invested 5.3 billion dollars in Mounjaro manufacturing capacity before demand materialized. Novo Nordisk did not. Lilly captured the category.
Most pharma forecasts skip patient flow modeling. The result is a forecast that is structurally incomplete.
Eligible and accessible patients are not the same. The gap is where most NPV evaporates.
Read Deeper
Articles in this collection.
Pharma, Business
The Field Force Reckoning: Why Pharma Is Cutting 50% of Its Reps by 2028
Pfizer cut 7,500 reps in 2024. Bayer announced 1,500 in early 2026. Sanofi cut 800 in March. The era of the 600-rep field force is ending. Here is what is replacing it.
May 5 · 3 min read
Pharma, Business
The Patient Your Pharma Forecast Forgot
Pharma forecasts are built in three stages by three different teams. The third arrives too late to change anything. Here is why and what to fix.
Apr 15 · 3 min read
Pharma, Business
Why 66% of Drug Launches Miss Their Forecast in 2026
Two thirds of pharma drug launches miss first year sales targets. The real reason is not the molecule. It is the commercial system around it.
Mar 25 · 3 min read
Questions
What people ask about pharma launches.
Want to talk about how this applies to your organization?
30 minute call. No deck. We will figure out if I can help.